StockData
Gilead Sciences, Inc. logo

Gilead Sciences, Inc.

GILDNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026Score 11/30105% above fair value
$170.33−0.35 (-0.21%)

Close on Nov 2, 2026Market cap $211.20BP/E –Yield 1.86%

Gilead Sciences In-process research and development impairment charges by Quarter

In-process research and development (IPR&D) impairment charges ($M) ($M)

QuarterlyAnnual

Gilead Sciences In-process research and development impairment charges: $12,043M in Q2 2026, up 19,642.6% from a year earlier. That is the highest of the 36 quarters on record here.

Latest, Q2 2026
12,043
Period ended Jun 30, 2026
Change on a year earlier
+19,642.6%
61 in Q2 2025
History
36 quarters
Since Q1 2015
Sources
27
Documents cited below

Where the Q2 2026 figure comes from

Calculated from reported figures: quarter = year-to-date − previous year-to-date (cash flow statement)

Source: Form 10-Q (filed 2026-08-06) ↗

Reported in Form 10-Q / 10-K Consolidated Statements of Operations.

Quarterly history

Hover a value to see the sentence it was read from; calculated values show their formula

PeriodEndedIn-process research and development (IPR&D) impairment charges ($M) ($M)Year on yearSource
Q2 2026Jun 30, 202612,043+19,642.6%Form 10-Q (filed 2026-08-06) ↗
Q1 2026Mar 31, 2026107-57.7%Form 10-Q (filed 2026-05-07) ↗
Q4 2025Dec 31, 2025539-5,000.0%Form 10-K (filed 2026-02-24) ↗
Q3 2025Sep 30, 2025170-66.3%Form 10-Q (filed 2025-11-07) ↗
Q2 2025Jun 30, 202561+60.5%Form 10-Q (filed 2025-08-07) ↗
Q1 2025Mar 31, 2025253-93.9%Form 10-Q (filed 2026-05-07) ↗
Q4 2024Dec 31, 2024-11-103.2%Form 10-K (filed 2026-02-24) ↗
Q3 2024Sep 30, 2024505+454.9%Form 10-Q (filed 2025-11-07) ↗
Q2 2024Jun 30, 202438-83.9%Form 10-Q (filed 2025-08-07) ↗
Q1 2024Mar 31, 20244,131+758.8%Form 10-Q (filed 2025-05-07) ↗
Q4 2023Dec 31, 2023347+119.6%Form 10-K (filed 2026-02-24) ↗
Q3 2023Sep 30, 202391-79.7%Form 10-Q (filed 2024-11-12) ↗
Q2 2023Jun 30, 2023236-28.5%Form 10-Q (filed 2024-08-08) ↗
Q1 2023Mar 31, 2023481-82.2%Form 10-Q (filed 2024-05-08) ↗
Q4 2022Dec 31, 2022158–Form 10-K (filed 2025-02-28) ↗
Q3 2022Sep 30, 2022448–Form 10-Q (filed 2023-11-07) ↗

Cite this data

StockData. (2026). Gilead Sciences In-process research and development impairment charges ($M), quarterly Q1 2015–Q2 2026 [Data set]. Compiled from Gilead Sciences SEC filings and investor materials. https://stockdatahq.com/stocks/gild/kpis/iprd-impairment-exp

See every metric in the Gilead Sciences KPI table. Data updated Oct 29, 2026.